Genocea Biosciences Inc (NASDAQ: GNCA) is having a great start to the trading session this morning, and for good reason. The company announced a clinical update that excited investors and sending the stock screaming for the top. Today, we’ll talk about:
- The clinical update;
- what we’re seeing from GNCA stock as a result; and
- what we’ll be watching for ahead.
GNCA Heads Up On Clinical Update
As mentioned above, Genocea Biosciences is having a great start to the trading session this morning after announcing a clinical update. In a press release issued early this morning, the company announced the dosing of the first patients in its Phase 1/2a clinical trial.
During the trial, GNCA is assessing the safety, immunogenicity, and clinical efficacy of GEN-009. GEN-009 is the company’s neoantigen cancer vaccine candidate. In the release, the comapny also said that it has completed the enrollment of patients into the first part of the clinical trial.
In a statement, Tom Davis, M.D., CMO at GNCA, had the following to offer:
Dosing the first patients with our GEN-009 vaccine represents a significant milestone for Genocea… Importantly, our GEN-009 vaccines use our ATLAS™ platform for neoantigen identification. Unlike machine-based approaches that predict neoantigens and only evaluate the patient’s tumor, ATLAS also uses each patient’s own immune cells not only to identify true neoantigens that already trigger anti-tumor cytokine responses, but also to eliminate “inhibitory” antigens that are frequently selected for vaccine inclusion by such in silico approaches. I am grateful to the patients eager to participate in our trial, to our investigators, and to my colleagues here at Genocea for creating the first vaccine that is genuinely personalized to each individual’s T cells and their tumor mutations.
With Part A of the trial now fully enrolled, we are in a better position to predict when we will have the first immunogenicity data from these patients. As a result, we are updating our guidance today and look forward to reporting top-line results from this part of the study late in the second quarter of this year or early in the third quarter.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. In the case of Genocea Biosciences, the news proved to be overwhelmingly positive. After all, the announcement shows that the company’s Phase 1/2a clinical trial is headed in the right direction, leading to excitement among investors. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:05), GNCA is trading at $0.33 per share after a gain of $0.043 per share or 15.06% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the iWatch Markets team will continue to keep a close eye on GNCA. In particular, we’re interested in following the story surrounding the company’s continued work to bring its cancer vaccine candidate to market. After all, today’s news shows that the company is progressing through the development process. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the iWatch Markets mailing list below!